

DEPARTMENT OF IMMUNOFLUOROMETRY

MATERNAL SERUM SCREENING-1T QUAD WITH PRE ECLAMPSIA(PLGF+PAPP-A+FREE BETAHCG+AFP+NT) , SERUM

*Method - Time resolved Immunofluorometry on Auto Delfia*Risk ratio calculated using LifeCycle 7.0

MATERNAL DETAILS		RESULT	UNITS
NUMBER OF FETUSES		1	
WEIGHT		75.4	Kg
H/O SMOKING		NO	
ETHNIC ORIGIN		ASIAN	
LMP DATE		18/12/2024	
AGE AT TERM		24/03	YEARS/MONTHS
GESTATION AT SAMPLE DATE		12/3	
INSULIN DEPENDENT DIABETES		NO	
H/O CHRONIC HYPERTENSION		UNKNOWN	
MAP		98.33	mm/Hg
<hr/>			
USG DETAILS			
DATE OF ULTRASOUND		04/03/2025	
GESTATIONAL AGE ON USG		11/0	WEEKS/DAYS
NUCHAL TRANSLUCENCY (NT)			mm
UTERINE ARTERY PI MoM			
<hr/>			
BIOCHEMICAL RESULTS		RESULT	UNITS
			CORR. MOM
PAPP-A		3830	mIU/L
BETA HCG		19.5	ng/mL
PLGF		122	pg/mL
ALPHA FETOPROTEIN (AFP)		17.1	U/mL
<hr/>			

DEPARTMENT OF IMMUNOFLUOROMETRY

DISORDER - ANEUPLOIDY SCREEN	RISK RATIO	RISK CATEGORY	SCREEN RESULT
DOWN'S SYNDROME	1:100000	LOW	SCREEN NEGATIVE
EDWARD'S SYNDROME	1:100000	LOW	SCREEN NEGATIVE
PATAU'S SYNDROME	1:100000	LOW	SCREEN NEGATIVE
DISORDER - PRE ECLAMPSIA SCREEN	RISK RATIO	CUT OFF	RISK CATEGORY
PE <32 WEEKS	1:13996	1:100	LOW
PE <37 WEEKS	1:342	1:100	LOW

FIRST TRIMESTER QUAD

Interpretation:-

1. The risks are calculated based on ultrasound gestational age, biochemical results, NT measurement, patient demographics and other risk factors such as IDD.
2. Patient specific risks are generated as analytical MoM (Multiples of Median) values, using Fetal Medicine Foundation (FMF) approved assays and software LIFECYCLE version 7.0 from Perkin Elmer.
3. A screen positive result occurs when the risk for Down's syndrome exceeds 1:250, when risk for Trisomy 13, Trisomy 18, Turner's syndrome exceeds 1:100 or when AFP MoM exceeds 2.5.

Limitations:-

1. The results of this test represent only risks and not diagnostic outcomes. Increased risk does not mean that the baby is affected, and further tests must be performed before a firm diagnosis can be made. A low risk does not exclude possibility of Down's syndrome or other abnormalities, as risk assessment does not detect all affected pregnancies.
2. If the history provided is not correct, it is advisable to ask for repeat risk calculations.

Associated tests:-

1. Integrated (first and second trimester) maternal serum screening.
2. NIPT- Non-invasive Prenatal Screening test - from maternal blood for aneuploidy screening.

PRE ECLAMPSIA SCREEN

DEPARTMENT OF IMMUNOFLUOROMETRY

Interpretation:-

1. In normal uncomplicated pregnancy free, unbound PIGF levels increase during the first and second trimester and then decline.
2. The predictive value of Preeclampsia may vary with subjective findings such as maternal history and mean arterial blood pressure (MAP), and ultrasound marker (Uterine Artery Pulsatility Index) results can be improved by adjusting the measured PIGF level for maternal history and characteristics.
3. Effective screening for early-onset PE at 11-13 weeks can be achieved in the first-trimester of pregnancy with a DR of about 95% and a FPR of 10%, when combining PIGF results with maternal history, MAP and uAD.

*** End Of Report ***

Requestor: Self, -

REQUESTOR TYPE: Hospital	REQUESTOR: Self	DOCTOR: -	FACILITY: -
REQUESTOR CODE: 099	REQUESTOR PHONE 1: -		

Patient DGRL.0000446232: -, Mrs.RAKSHITHA

PATIENT ID: DGRL.0000446232	LAST NAME: -	FIRST NAME: Mrs.RAKSHITHA	BIRTH DATE: 20/06/2001
ETHNICITY: Asian	ADDRESS 1: -	CITY: -	POSTAL CODE: -

Pregnancy, Calculated EDD: 23/09/2025 (MAEDD: 24.26)

MAEDD: 24.26	CALCULATED EDD: 23/09/2025	GEST. DATE: 17/12/2024	SELECTED GEST. METHOD: CRL
LMP DATE: 18/12/2024	SMOKING STATUS: Non smoker	INSULIN DEP. DIABETIC: No	NO. OF FETUSES: 1
MONOZYGOUS: No	CHORIONICITY: -	CORRECTED BY CHORIONICITY: -	FERTILIZATION DATE: -
ASSISTANCE METHOD: -	TRANSFER DATE: -	EGG EXTRACTION DATE: -	EGG DONOR DOB: -
AGE AT EXTRACTION: -	PAST T21 - DOWN'S SYNDROME: -	PAST T18 - EDWARDS' SYNDROME: -	PAST T13 - PATAU'S SYNDROME: -
PAST CDLS - CORNELIA DE LANGE SYNDROME: -	PAST SLOS - SMITH-LEMLI-OPITZ SYNDROME: -	PAST TR - TRIPLOIDY: -	PAST TS - TURNER'S SYNDROME: -
RISK ASSESSED: At term	SCREENING PROTOCOL: Screening_4.0		

Biochemistry

SAMPLE ID: IF00635119	SPECIMEN COLLECTED: 14/03/2025	WEIGHT [KG]: 75.4	GEST. AT SAMPLE DATE (W + D): 12 w 3 d
SAMPLE TYPE: -			

Ultrasound

SCAN DATE: 04/03/2025	CRL: 43.1	BPD: -	HC: -
GEST. AT SAMPLE DATE (W + D): 11 w 0 d	CRL (#2): -	BPD (#2): -	HC (#2): -
GEST. AT MANUAL ENTRY (W + D): 0 w 0 d	SAMPLE TYPE: -	WEIGHT [KG]: -	

Blood pressure, Gest. at sample date (w + d): 12 w 3 d


TIME MEASURED: 14/03/2025	LEFT SYST #1: 120	LEFT DIAST #1: 80	LEFT SYST #2: -	LEFT DIAST #2: -	MAP [MMHG]: 98.33
WEIGHT [KG]: -	RIGHT SYST #1: 130	RIGHT DIAST #1: 90	RIGHT SYST #2: -	RIGHT DIAST #2: -	CORR. MOM: 1.13

Tests

TEST	SAMPLE ID	DATE	GEST. AT SAMPLE DATE (W + D)	VALUE	UNIT	CORR. MOM	WEIGHT [KG]
AFP (Signed)	IF00635119	14/03/2025	12 w 3 d	17.1	U/mL	1.51	75.4
hCGb (Signed)	IF00635119	14/03/2025	12 w 3 d	19.5	ng/mL	0.63	75.4
PAPP-A (Signed)	IF00635119	14/03/2025	12 w 3 d	3830	mU/L	1.79	75.4
PIGF (Signed)	IF00635119	14/03/2025	12 w 3 d	122	pg/mL	1.96	75.4

Risks, Risk assessed: At term

RISK NAME:	RISK RESULT:	RISK:	TWIN RISK RESULT:	TWIN RISK:	AGE RISK:	CUT-OFF:
T21 (Calculated)	Low	1:100000	-	-	1:1416	1:250
T18 (Calculated)	Low	1:100000	-	-	1:12740	1:100
T13 (Calculated)	Low	1:100000	-	-	1:38268	1:100
PE < 32 (Calculated)	Low	1:13996	-	-	1:758	1:100
PE < 37 (Calculated)	Low	1:342	-	-	1:88	1:100



PLEASE NOTE:

TERMS AND CONDITIONS GOVERNING THIS REPORT

1. Reported results are for information and interpretation of the referring doctor or such other medical professionals, who understand reporting units, reference ranges and limitation of technologies. Laboratories not be responsible for any interpretation whatsoever.
2. It is presumed that the tests performed are, on the specimen / sample being to the patient named or identified and the verifications of particulars have been confirmed by the patient or his / her representative at the point of generation of said specimen.
3. The reported results are restricted to the given specimen only. Results may vary from lab to lab and from time to time for the same parameter for the same patient (within subject biological variation).
4. The patient details along with their results in certain cases like notifiable diseases and as per local regulatory requirements will be communicated to the assigned regulatory bodies.
5. The patient samples can be used as part of internal quality control, test verification, data analysis purposes within the testing scope of the laboratory.
6. This report is not valid for medico legal purposes. It is performed to facilitate medical diagnosis only.